PUBLIC COMPANY
save$PRLDPrelude Therapeutics Inc
$PRLDWilmington, DE, USupdated 15d ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 1
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
- phase2A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
- phase1A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
- phase1A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
- phase1PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
- phase1A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
- phase1PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
- phase1A Study of PRT2527 in Participants With Advanced Solid Tumors
Insider activity
source: SEC Form 4🐶 Hiring Signal
News
- Pathos AI pads pipeline with $2.2B Alphamab deal, AstraZeneca pactPathos AI has agreed to pay $125 million for a bispecific antibody-drug conjugate from China’s Alphamab Oncology, while adding a Big Pharma partner in the form of AstraZeneca.fiercebiotech · 10d ago
- Incyte ditches phase 1-stage JAK inhibitor to pursue next-gen optionsIncyte has ditched a JAK2 inhibitor in phase 1 development for a rare blood cancer in favor of “next-generation” replacements.fiercebiotech · 17d ago
Data sources
last refreshed 3m ago
Found something off?
comments(0)
5-min edit window · permanent after that